We are live on ! Find out more

STAAR Surgical

STAA

Market cap $1.16B

23.07 USD

+0.41

1.81%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

23.07

0.00

0%

1 day

1.81%

5 days

-0.3%

1 month

-11.88%

3 months

-18.68%

6 months

27.6%

Year to date

-2.25%

1 year

-16.62%

5 years

-83.47%

10 years

166.4%

About: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

Employees: 957

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 28.6%

Neutral 57.1%

Negative 14.3%

STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent, multi-market migration toward implantable lens correction driven by durable tailwinds on the demand and clinical sides of the market. The report examines patient.

STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer. "David Bailey doesn't just know STAAR, he helped change the trajectory of the entir.

STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer

STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer. "Evolving STAAR from a single-product focus into a multi-product platform is cent.

STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer

Zacks Investment Research

Deciphering Staar Surgical (STAA) International Revenue Trends

Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Deciphering Staar Surgical (STAA) International Revenue Trends

STAAR Surgical Q2 Earnings Call Highlights

STAAR Surgical NASDAQ: STAA reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company's strongest first half of revenue performance.

STAAR Surgical Q2 Earnings Call Highlights

STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript

STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript

STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates

Staar Surgical (STAA) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to a loss of $0.07 per share a year ago.

Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates

STAAR Surgical Reports Second Quarter 2026 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended July 3, 2026. Second Quarter 2026 Financial Overview Net sales of $93.5 million, up 111% Y/Y Net sales excluding China of $41.2 million, up 6.0% Y/Y China sales of $52.3 million up over 100%, 10% sequentially APAC sales up 189% Y/Y, ex-China sales up.

STAAR Surgical Reports Second Quarter 2026 Results

Zacks Investment Research

Staar Surgical (STAA) Upgraded to Strong Buy: What Does It Mean for the Stock?

Staar Surgical (STAA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Staar Surgical (STAA) Upgraded to Strong Buy: What Does It Mean for the Stock?

STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that following an extensive global search, its Board of Directors (the "Board") has appointed Warren Foust as President and Chief Executive Officer and a new member of the Board of Directors, effective August 4, 2026. Mr. Foust joined STAAR in April 2023 and h.

STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

See News Rankings

Price charts implemented using Lightweight Charts™